GLP-1 Pricing Pressure and UK Political Risk
Novo Nordisk shares rally as Hims and Hers withdraws a compounding GLP-1 plan following FDA threats. Meanwhile, UK political instability driven by Epstein file fallout is increasing government borrowing costs and signaling market volatility.